Oleclumab
Monoclonal antibody
- none
- 1803176-05-7
- none
- 5CRY01URYQ
- D10963
Oleclumab (INN;[1] development code MEDI9447) is a human monoclonal antibody targeting the ectonucleotidase CD73 that was designed for the treatment of pancreatic and colorectal and other cancers.[2]
This drug was developed by MedImmune/AstraZeneca.[3]
References
- ^ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 116" (PDF). WHO Drug Information. 30 (4).
- ^ ClinicalTrial.gov for Oleclumab
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Oleclumab, American Medical Association.
- v
- t
- e
